HomeClinical TopicsFDA approves Afrezza

FDA approves Afrezza

On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

menopause and sleep problems

Menopause and Sleep Problems

Data shows that sleep disturbances increase in prevalence during the menopausal transition, with the most common complaint being nighttime awakenings. Take our quick three-question survey...